• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Glaukos Corporation

    8/20/25 4:15:43 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care
    Get the next $GKOS alert in real time by email
    S-8 1 gkos-20250820xs8.htm S-8

    As filed with the Securities and Exchange Commission on August 20, 2025

    Registration No. __________________

    ​

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549


    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933


    Glaukos Corporation

    (Exact name of registrant as specified in its charter)


    ​

    ​

    ​

    Delaware

    33-0945406

    (State or other jurisdiction of incorporation or organization)

    (I.R.S. Employer Identification No.)

    ​

    One Glaukos Way

    Aliso Viejo, California 92656

    (Address, including zip code, of Principal Executive Offices)


    Glaukos Corporation 2015 Employee Stock Purchase Plan

    (Full title of the plan)


    Thomas W. Burns

    CEO & Chairman of the Board of Directors

    One Glaukos Way

    Aliso Viejo, California 92656

    (949) 367-9600

    (Name, address and telephone number, including area code, of agent for service)

    COPY TO:

    Shelly A. Heyduk

    O’Melveny & Myers LLP

    610 Newport Center Drive, Suite 1700

    Newport Beach, California 92660

    (949) 823-6900


    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of ‘‘large accelerated filer,’’ ‘‘accelerated filer,’’ ‘‘smaller reporting company’’ and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

    ​

    ​

    ​

    ​

    ​

    ⌧ Large accelerated filer

    ◻ Accelerated filer

    ◻ Non-accelerated filer

    ◻ Smaller reporting company

    ​

    ​

    ​

    ◻ Emerging growth company

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

    ​

    ​

    ​

    ​


    EXPLANATORY NOTE

    This Registration Statement is filed by Glaukos Corporation, a Delaware corporation (the “Company” or “Registrant”), to register additional securities issuable pursuant to the Glaukos Corporation 2015 Employee Stock Purchase Plan (the “ESPP”) and consists of only those items required by General Instruction E to Form S-8.


    PART I

    INFORMATION REQUIRED IN THE

    SECTION 10(a) PROSPECTUS

    The document(s) containing the information specified in Part I of Form S-8 will be sent or given to participants as specified by Securities Act Rule 428(b)(1).

    ​


    PART II

    INFORMATION REQUIRED IN THE

    REGISTRATION STATEMENT

    Item 3.

    Incorporation of Certain Documents by Reference

    The following documents of the Company filed with the Securities and Exchange Commission (the “Commission”) are incorporated herein by reference:

    a)The Company’s Registration Statements on Form S-8, filed with the Commission on June 30, 2015, June 17, 2016, May 10, 2018, March 1, 2019, March 9, 2020, March 11, 2021, March 8, 2022, March 10, 2023, and March 15, 2024 (Commission File Nos. 333-205372, 333-212106, 333-224822, 333-230017, 333-237030, 333-254141, 333-263373, 333-270453, and 333-278005, respectively);
    b)The Company’s Annual Report on Form 10-K for its fiscal year ended December 31, 2024, filed with the Commission on February 25, 2025 (Commission File No. 001-37463);
    c)The portions of the Company’s Definitive Proxy Statement on Schedule 14A, filed with the Commission on April 15, 2025, that are incorporated by reference in Part III of the Company’s Annual Report on Form 10-K for its fiscal year ended December 31, 2024 (Commission File No. 001-37463);
    d)The Company’s Quarterly Reports on Form 10-Q for its fiscal quarters ended March 31, 2025 and June 30, 2025, filed with the Commission on May 1, 2025 and August 4, 2025, respectively (each, Commission File No. 001-37463);
    e)The Company’s Current Report on Form 8-K, filed with the Commission on June 3, 2025 (Commission File No. 001-37463, only as to the information “filed” with the Commission thereunder for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and not as to information “furnished” thereunder); and
    f)The description of the Company’s common stock, par value $0.001 per share (the “Common Stock”) contained in its Registration Statement on Form 8-A filed with the Commission on June 22, 2015, as modified by the description of the Company’s Common Stock contained in Exhibit 4.3 to the Company’s Annual Report on Form 10-K for its fiscal year ended December 31, 2020, filed with the Commission on March 1, 2021 (each, Commission File No. 001-37463), and any other amendment or report filed for the purpose of updating such description.

    All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with Commission rules shall not be deemed incorporated by reference into this Registration Statement. Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or


    superseded shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.

    Item 5.

    Interests of Named Experts and Counsel

    The validity of the issuance of Common Stock registered hereby is passed on for the Company by Robert Davis. Mr. Davis is the Senior Vice President, General Counsel and Business Development of the Company and is compensated by the Company as an employee. Mr. Davis owns 14,647 shares of Common Stock, Company stock options to acquire up to an additional 119,615 shares of Common Stock and 21,850 restricted stock units that, when vested, will be delivered in the form of shares of Common Stock of the Company. Mr. Davis is eligible to receive stock awards by the Company under its 2015 Amended and Restated Omnibus Incentive Compensation Plan and is eligible to participate in the ESPP.

    Item 8.

    Exhibits

    See the Exhibit Index included in this Registration Statement, which is incorporated herein by reference.

    ​

    EXHIBIT INDEX

    ​

    ​

    ​

    Exhibit
    Number

        

    Description of Exhibit

    ​

    ​

    ​

    4.1

    ​

    Glaukos Corporation 2015 Employee Stock Purchase Plan. (Filed as Exhibit 10.16 to Amendment No. 2 to the Company’s Registration Statement on Form S-1, filed with the Commission on June 15, 2015 (Commission File No. 333-204091) and incorporated herein by this reference.)

    ​

    ​

    ​

    5.

    ​

    Opinion of Counsel (opinion re legality).

    ​

    ​

    ​

    23.1

    ​

    Consent of Independent Registered Public Accounting Firm.

    ​

    ​

    ​

    23.2

    ​

    Consent of Counsel (included in Exhibit 5).

    ​

    ​

    ​

    24.

    ​

    Power of Attorney (included in this Registration Statement under “Signatures”).

    ​

    ​

    ​

    107.

    ​

    Filing Fee Table

    ​

    ​

    ​


    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Form S-8 Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Aliso Viejo, State of California, on August 20, 2025.

    ​

    ​

    ​

    GLAUKOS CORPORATION

    ​

    ​

    ​

    By:

    /s/ Thomas W. Burns

    ​

    Thomas W. Burns

    ​

    CEO & Chairman of the Board of Directors

    ​

    POWER OF ATTORNEY

    Each person whose signature appears below constitutes and appoints Thomas W. Burns, Alex R. Thurman, and Robert L. Davis, and each of them, acting individually and without the other, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments, exhibits thereto and other documents in connection therewith) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them individually, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.


    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

    ​

    ​

    Signature

        

    Title

        

    Date

    ​

    ​

    ​

    ​

    ​

    /s/ Thomas W. Burns

    ​

    CEO and Chairman of the Board of Directors

    ​

    August 20, 2025

    Thomas W. Burns

    ​

    (Principal Executive Officer)

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Alex R. Thurman

    ​

    Senior Vice President and Chief Financial Officer

    ​

    August 20, 2025

    Alex R. Thurman

    ​

    (Principal Financial and Accounting Officer)

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Mark J. Foley

    ​

    Lead Independent Director

    ​

    August 20, 2025

    Mark J. Foley

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ David F. Hoffmeister

    ​

    Director

    ​

    August 20, 2025

    David F. Hoffmeister

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Gilbert H. Kliman

    ​

    Director

    ​

    August 20, 2025

    Gilbert H. Kliman, M.D.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Marc A. Stapley

    ​

    Director

    ​

    August 20, 2025

    Marc A. Stapley

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Denice M. Torres

    ​

    Director

    ​

    August 20, 2025

    Denice M. Torres

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Aimee S. Weisner

    ​

    Director

    ​

    August 20, 2025

    Aimee S. Weisner

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Leana S. Wen

    ​

    Director

    ​

    August 20, 2025

    Leana S. Wen, M.D.

    ​

    ​

    ​

    ​

    ​


    Get the next $GKOS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GKOS

    DatePrice TargetRatingAnalyst
    5/1/2025$86.00Overweight → Equal Weight
    Wells Fargo
    2/19/2025$140.00 → $200.00Neutral → Outperform
    Mizuho
    12/11/2024$132.00 → $162.00Neutral → Buy
    Citigroup
    12/6/2024$182.00Buy
    UBS
    12/2/2024$120.00Equal-Weight → Underweight
    Morgan Stanley
    7/10/2024$132.00Buy → Neutral
    Citigroup
    5/6/2024$84.00 → $125.00Hold → Buy
    Jefferies
    12/21/2023$66.00 → $91.00Neutral → Overweight
    JP Morgan
    More analyst ratings

    $GKOS
    SEC Filings

    View All

    SEC Form S-8 filed by Glaukos Corporation

    S-8 - GLAUKOS Corp (0001192448) (Filer)

    8/20/25 4:15:43 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by Glaukos Corporation

    SCHEDULE 13G - GLAUKOS Corp (0001192448) (Subject)

    8/12/25 10:34:25 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - GLAUKOS Corp (0001192448) (Filer)

    8/12/25 7:00:14 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Glaukos Announces Participation in Wells Fargo Healthcare Conference

    Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 10:15 a.m. ET in Boston, MA. A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com. About Glaukos Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the

    8/13/25 7:00:00 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos Announces Second Quarter 2025 Financial Results

    Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2025. Key highlights include: Record net sales of $124.1 million in Q2 2025 increased 30% year-over-year on a reported basis and 29% year-over-year on a constant currency basis. Glaucoma record net sales of $103.5 million in Q2 2025 increased 36% year-over-year. U.S. Glaucoma record net sales of $72.3 million in Q2 2025 increased 45% year-over-year. Gross margin of approximately 78% and non-GAAP gross margin of approxima

    7/30/25 4:05:00 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30

    Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2025 financial results after the market close on Wednesday, July 30, 2025. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on July 30, 2025. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 800-715-9871 (U.S.) or 646-307-1963 (In

    7/9/25 7:00:00 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for IDOSE TR issued to GLAUKOS CORP

    Submission status for GLAUKOS CORP's drug IDOSE TR (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form

    12/15/23 11:41:09 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    FDA Approval for TRAVOPROST issued to GLAUKOS CORP

    Submission status for GLAUKOS CORP's drug TRAVOPROST (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form

    12/14/23 7:41:03 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hoffmeister David F exercised 25,000 shares at a strike of $32.00, increasing direct ownership by 361% to 31,918 units (SEC Form 4)

    4 - GLAUKOS Corp (0001192448) (Issuer)

    6/13/25 7:43:41 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Director Foley Mark J was granted 2,972 shares, increasing direct ownership by 64% to 57,221 units (SEC Form 4)

    4 - GLAUKOS Corp (0001192448) (Issuer)

    6/2/25 4:44:12 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Director Hoffmeister David F was granted 2,665 shares, increasing direct ownership by 63% to 6,918 units (SEC Form 4)

    4 - GLAUKOS Corp (0001192448) (Issuer)

    6/2/25 4:43:25 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Leadership Updates

    Live Leadership Updates

    View All

    OnCusp Therapeutics Announces Appointment of Robert Forrester and Chau Khuong to Board of Directors

    NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneur Robert Forrester and venture capitalist Chau Khuong as independent board directors. "We are delighted to have Robert and Chau, two seasoned leaders with a wealth of insights and expertise, to join OnCusp's Board. Both are highly regarded and deeply connected in the biotech and investment community," said Dr. Bing Yuan, Chairman and CEO of OnCusp. "Each of these individuals brings unique skill sets to our Board and will be instrumental to advancing OnCusp through se

    1/4/23 8:00:00 AM ET
    $BLU
    $GKOS
    $INSP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Election of Thomas W. Burns as New Chairman and Mark J. Foley as Lead Independent Director

    Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that William J. Link, Ph.D., will be retiring as Chairman of the Board, effective December 31, 2021. Dr. Link joined Glaukos' Board and has served as Chairman since June 2001. In connection with Dr. Link's retirement, the Board has appointed Thomas W. Burns, Glaukos' President and Chief Executive Officer and a director on the Board since 2002, to serve as the company's Chairman of the Board, effective upon Dr. Link's retirement on December 31, 2021. Mr. Burns will continue to serve as th

    12/20/21 4:15:00 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos Appoints Denice Torres and Dr. Leana Wen to its Board of Directors

    SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the appointment of Denice Torres and Dr. Leana Wen to its Board of Directors, effective today. With the addition of these two directors, Glaukos’ Board of Directors will be comprised of nine directors, eight of whom are independent. “We are delighted and honored to welcome these highly accomplished professionals to the Glaukos Board. Each of these extraordinary women brings a wealth of relevant experience, perspective, leadership and wis

    3/1/21 4:10:00 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Glaukos Corporation

    SC 13G/A - GLAUKOS Corp (0001192448) (Subject)

    11/14/24 1:21:45 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Glaukos Corporation (Amendment)

    SC 13G/A - GLAUKOS Corp (0001192448) (Subject)

    2/14/24 3:55:55 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Glaukos Corporation (Amendment)

    SC 13G/A - GLAUKOS Corp (0001192448) (Subject)

    2/13/24 5:41:34 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Financials

    Live finance-specific insights

    View All

    Glaukos Announces Second Quarter 2025 Financial Results

    Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2025. Key highlights include: Record net sales of $124.1 million in Q2 2025 increased 30% year-over-year on a reported basis and 29% year-over-year on a constant currency basis. Glaucoma record net sales of $103.5 million in Q2 2025 increased 36% year-over-year. U.S. Glaucoma record net sales of $72.3 million in Q2 2025 increased 45% year-over-year. Gross margin of approximately 78% and non-GAAP gross margin of approxima

    7/30/25 4:05:00 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30

    Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2025 financial results after the market close on Wednesday, July 30, 2025. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on July 30, 2025. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 800-715-9871 (U.S.) or 646-307-1963 (In

    7/9/25 7:00:00 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos Announces First Quarter 2025 Financial Results

    Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2025. Key highlights include: Record net sales of $106.7 million in Q1 2025 increased 25% year-over-year on a reported basis and 26% year-over-year on a constant currency basis. Glaucoma record net sales of $88.1 million in Q1 2025 increased 31% year-over-year. U.S. Glaucoma record net sales of $59.1 million in Q1 2025 increased 41% year-over-year. Gross margin of approximately 77% and non-GAAP gross margin of approximately

    4/30/25 4:05:00 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Glaukos downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Glaukos from Overweight to Equal Weight and set a new price target of $86.00

    5/1/25 7:44:23 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos upgraded by Mizuho with a new price target

    Mizuho upgraded Glaukos from Neutral to Outperform and set a new price target of $200.00 from $140.00 previously

    2/19/25 7:02:55 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos upgraded by Citigroup with a new price target

    Citigroup upgraded Glaukos from Neutral to Buy and set a new price target of $162.00 from $132.00 previously

    12/11/24 7:52:08 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care